Mode
Text Size
Log in / Sign up
N/A N=82 Basic Science

Fructose Consumption and Metabolic Dysregulation

Central Obesity · Hypertriglyceridemia

Enrolled (actual)
82
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fructose (Dietary_supplement)
Age
Adult · 20+ yrs
Sex
Male
Sponsor
Marja-Riitta Taskinen
Primary completion
May 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
TG Plasma AUC
1130; 1220 0.005 sig
PRIMARY
B48 Plasma AUC
7660; 8200 0.04 sig
PRIMARY
TG Plasma iAUC
377; 422 0.04 sig
SECONDARY
DNL
12.3; 16.5 0.005 sig
SECONDARY
ApoC-III
10.4; 11.2 0.006 sig
SECONDARY
β-OH Butyrate
0.699; 0.542 0.01 sig
SECONDARY
Liver Fat
6.66; 7.33 0.008 sig

Summary

High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be activated by fructose independently of insulin. However, it is still controversial whether fructose consumption increases DNL in man to the extent that it induces metabolic disturbances. Animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. The role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. The critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.

Eligibility Criteria

Inclusion Criteria

  • Body mass index 27-40
  • Waist > 96 cm
  • Age 20-60 years
  • Male

Exclusion Criteria

  • Smoking
  • Active health problems
  • Contraindications to MRI scanning
  • Bleeding tendency
  • Abnormal liver or renal function tests
  • Type 2 diabetes
  • Evidence of metabolic or viral liver disease
  • Alcohol intake > 21 units per week
  • Chronic medication except ones needed for stable hypertension
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01445730). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search